Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy

11.10.2018

Eidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

11.06.2018

Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results

10.29.2018

Eidos Therapeutics Receives Positive Opinion for Orphan Designation from the European Medicines Agency for AG10, a Potent Oral Stabilizer for the Treatment of Transthyretin Amyloidosis

10.26.2018

Data Published in Nature Communications Demonstrates CoA Therapeutics’ Potential to Treat Genetically Driven Pantothenate Kinase-Associated Neurodegeneration (PKAN)

10.23.2018

QED Therapeutics Presents Data for Infigratinib in Cholangiocarcinoma in Late Breaking Abstract at the European Society of Medical Oncology 2018 Congress

10.19.2018

PellePharm Presents Updated Data from Two Phase 2 Studies Demonstrating the Potential of Patidegib Topical Gel to Treat Basal Cell Carcinomas in Patients with Gorlin Syndrome and Patients with Non-Gorlin Sporadic BCCs

10.15.2018

Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

10.05.2018

FDA Grants Orphan Drug Designation to Eidos Therapeutics’ Product Candidate, AG10, for Treatment of Transthyretin Amyloidosis

10.03.2018

Eidos Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology

09.25.2018

PellePharm to Present at Cantor Fitzgerald Global Healthcare Conference

09.25.2018

Eidos Therapeutics Presents Data from its Phase 1 Clinical Trial of AG10 at the 22nd Annual Scientific Meeting of the Heart Failure Society of America

09.17.2018

Eidos Therapeutics Announces Publication of AG10 Molecular Design in Journal of Medicinal Chemistry

08.23.2018

PellePharm Shares Seminal Data Published in JCI Insight Identifying Clinical Marker for Inherited Cancer Susceptibility

08.17.2018

QED Tx – A New Company Working on a Treatment for Achondroplasia

08.15.2018

Eidos Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

08.07.2018

Eidos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

06.22.2018

Eidos Therapeutics Announces Pricing of Initial Public Offering

06.20.2018

NeuroVive Out-Licenses Targeted LHON Therapy to BridgeBio Pharma’s New Subsidiary Fortify Therapeutics

06.18.2018

BridgeBio Pharma launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

06.13.2018

news

Catch up on news from BridgeBio and its companies and follow developments about the promising treatments in our pipeline. Follow us on LinkedIn to keep up with all the latest news.

Links to an external site